Pomalidomide in primary intraocular lymphoma

Leuk Lymphoma. 2019 Jun;60(6):1584-1586. doi: 10.1080/10428194.2018.1538508. Epub 2019 Jan 11.

Authors

Jan-Paul Bohn¹, Wolfgang Willenbacher^{1

2}, Gertrud Haas³, Ines Peschel⁴, Herbert Oberacher⁵, Michael Steurer¹

Affiliations

¹ a Department of Internal Medicine V , Medical University of Innsbruck , Innsbruck , Austria.
² b Oncotyrol, Center for Personalized Cancer Medicine , Innsbruck , Austria.
³ c Department of Ophthalmology and Optometry , Medical University of Innsbruck , Innsbruck , Austria.
⁴ d Central Institute for Medical and Chemical Laboratory Diagnostics , Medical University of Innsbruck , Innsbruck , Austria.
⁵ e Institute of Legal Medicine and Core Facility Metabolomics , Medical University of Innsbruck , Innsbruck , Austria.

PMID: 30632826
DOI: 10.1080/10428194.2018.1538508

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / pharmacokinetics
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers
Biopsy
Female
Humans
Intraocular Lymphoma / diagnosis
Intraocular Lymphoma / drug therapy*
Retreatment
Thalidomide / administration & dosage
Thalidomide / adverse effects
Thalidomide / analogs & derivatives*
Thalidomide / pharmacokinetics
Thalidomide / therapeutic use
Treatment Outcome

Substances

Antineoplastic Agents
Biomarkers
Thalidomide
pomalidomide